.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Vorinostat - Generic Drug Details

« Back to Dashboard
Vorinostat is the generic ingredient in one branded drug marketed by Merck and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and twenty-seven patent family members in thirty-five countries.

There are two drug master file entries for vorinostat. One supplier is listed for this compound.

Summary for Generic Name: vorinostat

Tradenames:1
Patents:9
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list76
Clinical Trials: see list189
Patent Applications: see list3,947
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:vorinostat at DailyMed

Pharmacology for Ingredient: vorinostat

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes8,101,663► subscribe ► subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes7,851,509► subscribeY ► subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes8,093,295► subscribeY ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: vorinostat

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 20066,087,367► subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RE38506► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: vorinostat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,288,440Formulations of suberoylanilide hydroxamic acid and methods for producing same► subscribe
7,148,257Methods of treating mesothelioma with suberoylanilide hydroxamic acid► subscribe
7,847,122Polymorphs of suberoylanilide hydroxamic acid► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: vorinostat

Country Document Number Estimated Expiration
South Korea20080041307► subscribe
Japan2008519081► subscribe
Norway20070952► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc